Sanofi’s amcenestrant clinical failure will halt development
ADC评论
August 18, 2022
PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is
